The stakes are with your advanced cell or gene therapy program, and nothing about it is standard.
Study design, conduct, and regulatory all diverge from the classic path. This is the reason why sponsors need a partner who has navigated this terrain before.
Veristat has successfully supported more than 100 cell and gene therapy clinical trials and consulting projects in the past 5 years, with a global team of scientific experts adept at both strategy and execution across the clinical development journey.
100+
cell and gene therapy clinical trials successfully supported by Veristat.
Patient availability, product handling, manufacturing dependencies, long-term follow-up, safety, and regulatory requirements can each change the study path.
Veristat connects those realities to study design, evidence generation, and the decisions required to keep an advanced therapy program moving.
WHY VERISTAT
Advanced Therapies Require Special Regulatory Focus
Accelerated pathways and special designations can create opportunity, but they also raise the cost of unclear evidence or late regulatory alignment. Veristat helps sponsors connect ongoing agency engagement with study design, data strategy, and submission requirements, so each decision is grounded in the evidence regulators will need. In the past five years, Veristat has completed more than 20 cell and gene therapy clinical trial applications and marketing applications.
A Life-Changing Opportunity with No Standard Playbook
For patients with conditions that may be intractable to other treatments, advanced therapies offer extraordinary potential.
Bringing that potential to patients requires a development path that accounts for scientific unknowns, complex operations, evolving evidence, and a regulatory process that is rarely linear.
advanced therapies
Do not follow a classic route to market.
Demand more complex clinical program planning.
Can depend upon the right regulatory pathway.
Often use non-randomized or natural history trial design.
Require long-term follow-up rollover studies.
PROOF & RESOURCES
Learn More with These Resources
Advancing Revolutionary Therapies (ART) – Cell & Gene series
Listen now →
Data-Driven Strategies to Advance Development and Approval of ...
Learn More →
Flexibility Drives Progress in Rare Disease Gene Therapy Trial
Learn more →
Supporting Global Approval of a First-in-Class Gene Therapy ...
Learn more →
Which decision is creating the most risk in your advanced therapy program?
Bring us the regulatory pathway, study design, evidence, operational, or long-term follow-up questions in front of you. Veristat will help you connect it to the data and decisions required next.
Cell and gene therapies often use non-randomized or natural history trial designs, require long-term follow-up rollover studies, and depend heavily on selecting the right regulatory pathway, all of which differ from the classic route most standard clinical programs follow.
Veristat's team has deep expertise in accelerated approval pathways and in applying for and retaining special regulatory designations specific to advanced cell and gene therapy products, while maintaining ongoing engagement with global regulatory agencies as the landscape evolves.
Yes. Veristat has extensive global expertise supporting gene therapies, cell therapies, and tissue engineering programs, including work on one of the first gene therapies approved in the western world.
